<DOC>
	<DOCNO>NCT01542294</DOCNO>
	<brief_summary>The purpose study assess safety efficacy S-1 plus oxaliplatin combination chemotherapy base adverse event survival period perform phase I/II study combination patient D2 resection gastric cancer .</brief_summary>
	<brief_title>SOX Adjuvant Chemotherapy Resectable Gastric Cancer</brief_title>
	<detailed_description>This stage I/II study design evaluate appropriate dose S-1 plus fixed-dose oxaliplatin ( SOX regimen ) Patients D2 resection gastric cancer survival SOX regimen stage II-III patient ( AJCC 7th ) . To assess efficacy , data recurrence survival collect time enrollment 3 year surgery . To evaluate safety , data adverse event collect time enrollment 1 year surgery .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>2070 year Histologically proven adenocarcinoma stomach Curative D2 lymphadenectomy resection gastric cancer , start chemotherapy within 6 week surgery Stage II , III ( AJCC 7th edition ) Eastern Cooperative Oncology Group ( ECOG ) performance status 01 No prior chemotherapy radiotherapy Adequate bone marrow , renal , liver function Any evidence metastatic disease ( include presence tumor cell ascites ) . Previous cytotoxic chemotherapy , radiotherapy immunotherapy except corticosteroid , currently treat gastric cancer . Major surgery within 4 week prior study treatment start , lack complete recovery effect major surgery . Pregnant lactating woman . History another malignancy within last five year except cure basal cell carcinoma skin cure carcinoma insitu uterine cervix . Lack physical integrity upper gastrointestinal tract malabsorption syndrome likely influence absorption capecitabine , inability take oral medication . Organ allograft require immunosuppressive therapy . Serious uncontrolled intercurrent infection serious uncontrolled concomitant disease . Prior unanticipated severe reaction fluoropyrimidine therapy ( without document dihydropyrimidine dehydrogenase ( DPD ) deficiency ) patient know DPD deficiency . Hypersensitivity platinum compound component study medication . Received investigational drug agent/procedure , i.e . participation another trial , within 4 week enter trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>S-1</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>adjuvant chemotherapy</keyword>
</DOC>